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1. Introduction
  The liver is a vital organ present in vertebrates and some 
other animals, and is typically the largest visceral organ. 
The liver plays a major role in transforming and clearing 
chemicals and is susceptible to the toxicity from these 
agents. Some medicinal agents, when taken in overdoses 
and sometimes even when introduced within therapeutic 
ranges, may injure the organ. Chemicals that cause liver 
injury are called hepatotoxins[1]. Chemicals often cause 
subclinical injury to liver which manifests only as abnormal 
liver enzyme tests. Drug-induced hepatotoxicity represents 
a major clinical problem accounting for 50% of all cases of 
acute liver failure. Although the majority of cases of acute 
liver failure are due to intentional or unintentional misuse, 
16% are idiosyncratic[2]. Some of the inorganic compounds 
producing hepatotoxicity are arsenic, phosphorus, copper 
and iron. The organic agents include certain naturally-
occurring plant toxins such as pyrrolizidine alkaloids, 
mycotoxins and bacterial toxins. In addition, exposure 
to hepatotoxic compounds may be occupational, 
environmental or domestic that could be accidental, 
homicidal or suicidal ingestion[3]. 
2.  Hepatotoxicity
  Drugs continue to be pulled from the market with 
disturbing regularity because of late discovery of 
hepatotoxicity[4]. The mechanism of hepatic injury has 
been proposed to involve 2 pathways-direct hepatotoxicity 
and adverse immune reactions. In most instances, 
hepatic injury is initiated by the bioactivation of drugs to 
chemically reactive metabolites, which have the ability to 
interact with cellular macromolecules such as proteins, 
lipids, and nucleic acids, leading to protein dysfunction, 
lipid peroxidation, DNA damage and oxidative stress. 
Additionally, these reactive metabolites may induce 
disruption of ionic gradients and intracellular calcium 
stores, resulting in mitochondrial dysfunction and loss 
of energy production. Its dysfunction releases excessive 
amount of oxidants which in turn injures hepatic cells[5]. 
Hepatic cellular dysfunction and death also have the ability 
to initiate immunological reactions, including both innate 
and adaptive immune responses. Stress and damage to 
hepatocytes result in the release of signals that stimulate 
activation of other cells, particularly those of the innate 
immune system, including Kupffer cells (KC), natural killer 
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(NK) cells, and NKT cells. These cells contribute to the 
progression of liver injury by producing proinflammatory 
mediators and secreting chemokines to further recruit 
inflammatory cells to the liver. It has been demonstrated 
that various inflammatory cytokines, such as tumor necrosis 
factor (TNF)-毩, interferon (IFN)-毭, and interleukin (IL)-1毬
, produced during hepatic injury are involved in promoting 
tissue damage[6]. However, innate immune cells are also 
the main source of IL-10, IL-6, and certain prostaglandins, 
all of which have been shown to play a hepatoprotective 
role[7]. It is, therefore the delicate balance of inflammatory 
and hepatoprotective mediators produced after activation of 
the innate immune system that determines an individual’s 
susceptibility and adaptation to hepatic injury.
3. Evauluation of antihepatotoxic agents
  The therapeutic value, efficacy and toxicity of drugs may 
be evaluated in animals experimentally made sick, followed 
by clinical trials. Detailed biochemical and other in vitro 
assays are obligatory to establish the mechanism of action. 
Both in vivo and in vitro test systems are employed to assess 
antihepatotoxic or hepatoprotective activity. These systems 
measure the ability of the test drug to prevent or cure liver 
toxicity (induced by various hepatotoxins) in experimental 
animals (rats, mice etc.) [8]. 
4. In vitro models
  Fresh hepatocyte preparations and primary cultured 
hepatocytes are cultured to study the anti-hepatotoxic 
activity of drugs. Hepatocytes are treated with hepatotoxin 
and the effect of the test drug on the same is evaluated. The 
activities of the transaminases released into the medium are 
determined. An augmented activity of marker transaminases 
in the medium indicates liver damag. Parameters such as 
hepatocytes multiplication, morphology, macromolecular 
synthesis and oxygen consumption are determined[9]. 
5. In vivo models
  A toxic dose or repeated doses of a known hepatotoxin 
is administered to induce liver damage in experimental 
animals. The test substance is administered along with, 
prior to and/or after the toxin treatment. Liver damage and 
recovery from damage are assessed by quantifying serum 
marker enzymes, bilirubin, bile flow, histopathological 
changes and biochemical changes in liver. An augmented 
level of liver marker enzymes such as glutamate pyruvate 
transaminase (GPT), glutamate oxaloacetate transaminase 
(GOT) and alkaline phosphatase in the serum indicates liver 
damage[10]. Therapeutic efficacy of a drug against diverse 
hepatotoxins differs especially when their mechanism of 
action vary. Consequently, the efficacy of each drug has to 
be tested against hepatotoxins which act by varied methods. 
6. Hepatotoxic agents
  Various chemical agents normally used to induce 
hepatotoxicty in experimental animals for the evaluation of 
hepatoprotective agents are:
6.1. Acryl amide 
  Acrylamide (AA) is a water-soluble vinyl monomer 
used in the production and synthesis of polyacrylamides. 
Monomeric AA has been shown to cause diverse toxic effects 
in experimental animals. Acrylamide is carcinogenic to 
laboratory rodents and is described by the International 
Agency for Research of Cancer as a probable carcinogen to 
humans. In the human body, AA is oxidized to the epoxide 
glycidamide (2,3-epoxypro-pionamide) via an enzymatic 
reaction involving cytochrome P4502E1. AA undergoes 
biotransformation by conjugation with glutathione and is 
probably being the major route of detoxification. Daily dose 
of 6 mg/kg, ip for 15 d produces hepatotoxicity in female 
Sprague-Dawley rats[11]. 
6.2. Adriamycin
  Adriamycin (doxorubicin) is an antibiotic isolated from 
streptomyces peucetius var Cesius Adriamycin and is 
considered to be one of the most compelling drugs against 
a wide range of tumors. However, its clinical potential is 
contraindicated due to severe cytotoxic side effects Based on 
in vitro model of toxicity using isolated hepatocytes and liver 
microsomes, adriamycin has been shown to undergo redox 
cycling between semiquinone and quinone radicals during its 
oxidative metabolism. A single dose of 10 mg/kg body weight 
of adriamycin is given to rats to induce hepatotoxicity[12]. 
6.3. Alcohol
  Liver is among the organs most susceptible to the toxic 
effects of ethanol. Alcohol consumption is known to cause 
fatty infiltration, hepatitis and cirrhosis. Fat infiltration 
is a reversible phenomenon that occurs when alcohol 
replaces fatty acids in the mitochondria. Hepatitis and 
cirrhosis may occur because of enhanced lipid peroxidative 
reaction during the microsomal metabolism of ethanol. The 
mechanisms responsible for effects of alcohol, an increase in 
hepatic lipid peroxidation leads to alteration in membrane 
phospholipid composition. The effects of ethanol have been 
suggested to be a result of the enhanced generation of oxy 
free radicals during its oxidation in liver. The peroxidation 
of membrane lipids results in loss of membrane structure 
and integrity. These results in elevated levels of glutamyl 
transpeptidase, a membrane bound enzyme in serum. 
Ethanol inhibits glutathione peroxidase, decrease the activity 
of catalase, superoxide dismutase, along with increase in 
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levels of glutathione in liver[13]. The decrease in activity 
of antioxidant enzymes superoxide dismutase, glutathione 
peroxidase are speculated to be due to the damaging effects 
of free radicals produced following ethanol exposure or 
alternatively could be due to a direct effect of acetaldehyde, 
formed by oxidation of ethanol. Continuous administration 
of ethanol (7.9 g/kg body weight/d) for a period of 6 weeks 
induces liver damage in rats[14].
 
6.4. Alpha-naphthylisothiocyanate
  Alpha-Naphthylisothiocyanate (ANIT) injures bile duct 
epithelium and hepatic parenchymal cells in rats. It is 
commonly believed that ANIT undergoes bioactivation 
by hepatic, cytochrome P450-dependent mixed-function 
oxidases. Rats intoxicated once with ANIT (75 mg/kg, 
intraperitoneal (i.p.)) show liver cell damage and biliary 
cell damage with cholestasis at 24 h, but not 12 h, after 
intoxication[15]. 
6.5. Antitubercular drugs
  Drug induced hepatotoxicity is a potentially serious 
adverse effect of the currently used antitubercular 
therapeutic regimens containing Isoniazid (INH), Rifampicin 
and Pyrazinamide. Adverse effects of antitubercular therapy 
are sometimes potentiated by multiple drug regimens. Thus, 
though INH, Rifampicin and Pyrazinamide each in itself are 
potentially hepatotoxic, when given in combination, their 
toxic effect is enhanced. INH is metabolized to monoacetyl 
hydrazine, which is further metabolized to a toxic product 
by cytochrome P450 leading to hepatotoxicity. Patients on 
concurrent rifampicin therapy have an increased incidence 
of hepatitis[16]. This has been postulated due to rifampicin-
induced cytochrome P450 enzyme-induction, causing an 
increased production of the toxic metabolites from acetyl 
hydrazine (AcHz). Rifampicin also increases the metabolism 
of INH to isonicotinic acid and hydrazine, both of which are 
hepatotoxic.  The plasma half life of AcHz (metabolite of INH) 
is shortened by rifampicin and AcHz is quickly converted to 
its active metabolites by increasing the oxidative elimination 
rate of AcHz, which is related to the higher incidence of 
liver necrosis caused by INH and rifampicin in combination. 
Rifampicin induces hydrolysis pathway of INH metabolism 
into the hepatotoxic metabolite hydrazine. Pharmacokinetic 
interactions exist between rifampicin and pyrazinamide in 
tuberculosis patients, when these drugs are administered 
concomitantly. Pyrazinamide decrease the blood level of 
rifampicin by decreasing its bioavailability and increasing 
its clearance. Pyrazinamide, in combination with INH and 
rifampicin, appears to be associated with an increased 
incidence of hepatotoxicity[17]. 
6.6. Cadmium
  Cadmium, a heavy metal well known to be highly toxic 
to both humans and animals, is distributed widely in the 
environment due to its use in various industries. Some 
of the toxic effects of cadmium exposure are testicular 
atrophy, renal dysfunction, hepatic damage, hypertension, 
central nervous system injury and anemia. Cadmium may 
induce oxidative damage in different tissues by enhancing 
peroxidation of membrane lipids in tissues and altering 
the antioxidant systems of the cells. The peroxidative 
damage to the cell membrane may cause injury to cellular 
components due to the interaction of metal ions with the cell 
organelles[18]. Cadmium depletes glutathione and protein 
bound sulfhydryl groups resulting in enhanced production 
of reactive oxygen species such as superoxide ions, hydroxyl 
radicals and hydrogen peroxides. These reactive oxygen 
species result in increased lipid. Cadmium is given orally 
(3 mg/kg body weight/d) as cadmium chloride (CdCl2) for 3 
weeks to induce hepatotoxicity in rats[19]. 
6.7. Carbon tetrachloride
  Carbontetrachloride is metabolized by cytochrome P-450 in 
endoplasmic reticulum and mitochondria with the formation 
of CCl3O
- , a reactive oxidative free radical, which initiates 
lipid peroxidation.
   Administration of a single dose of CCl4 to a rat produces, 
within 24 h, a centrilobular necrosis and fatty changes. 
The poison reaches its maximum concentration in the liver 
within 3 h of administration. Thereafter, the level falls and 
by 24 h there is no CCl4 left in the liver. The development 
of necrosis is associated with leakage of hepatic enzymes 
into serum.  Dose of CCl4: 1 mL/kg body weight, i.p., 1:1 v/v 
mixture of CCl4 and olive oil[20]. 
6.8. Erythromycin
  Erythromycin estolate is a potent macrolide antibiotic, 
generates free radicals and has been reported to induce liver 
toxicity. Erythromycin when given as erythromycin stearate 
(100 mg/kg body weight for 14 d)[21] or erythromycin esolate 
(800 mg/kg/d for 15 d) to albino rats produces hepatotoxicity 
in them[22]. 
6.9. Galactosamine
  Galactosamine produces diffuse type of liver injury 
simulating viral hepatitis. It presumably disrupts the 
synthesis of essential uridylate nucleotides resulting in 
organelle injury and ultimately cell death. Depletion of 
those nucleotides would impede the normal synthesis of 
RNA and consequently would produce a decline in protein 
synthesis. This mechanism of toxicity brings about an 
increase in cell membrane permeability leading to enzyme 
leakage and eventually cell death. The cholestasis caused 
by galactosamine may be from its damaging effects on bile 
ducts or ductules or canalicular membrane of hepatocytes 
Galactosamine decrease the bile flow and its content i.e. 
bile salts, cholic acid and deoxycholic acid. Galactosamine 
reduces the number of viable hepatocytes as well as rate 
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of oxygen consumption. Hepatic injury is induced by 
intraperitoneal single dose injection of D-galactosamine 
(800 mg/kg) [23]. 
6.10. Lead
  Lead is known to disrupt the biological systems by altering 
the molecular interactions, cell signaling, and cellular 
function. Exposure to even low levels of lead may have 
potential hazardous effects on brain, liver, kidneys and 
testes. Autopsy studies of lead-exposed humans indicate 
that among soft tissue, liver is the largest repository (33%) of 
lead, followed by kidney. Lead-induced hepatic damage is 
mostly rooted in lipid peroxidation (LPO) and disturbance of 
the prooxidant-antioxidant balance by generation of reactive 
oxygen species (ROS). Hepatotoxicity can be induced by 
using lead acetate (550 ppm for 21 d in drinking water)[24] or 
lead nitrate (5 mg/kg body weight daily for 30 d) [25]. 
6.11. Microcystin
  Microcystin-LR, a cyclic heptapeptide synthesized by 
the blue-green algae, Microcystis aeruginosa, is a potent 
hepatotoxin. Pathological examination of livers from mice 
and rats that received microcystin-LR revealed severe, 
peracute, diffuse, centrilobular hepatocellular necrosis, and 
hemorrhage. Mice receiving sublethal doses of microcystin 
(20 毺g/kg) for 28 weeks developed neoplastic liver 
nodules[26]. 
6.12. Paracetamol
  It is a widely used analgesic and antipyretic drug, 
produces acute liver damage in high doses. Paracetamol 
administration causes necrosis of the centrilobular 
hepatocytes characterized by nuclear pyknosis and 
eosinophilic cytoplasm followed by large excessive 
hepatic lesion. The covalent binding of N-acetyl-P-
benzoquinoneimine, an oxidative product of paracetamol 
to sulphydryl groups of protein, result in lipid peroxidative 
degradation of glutathione level and thereby, produces cell 
necrosis in the liver. Dose of Paracetamol: 2 g/kg P.O[27]. 
6.13. Phalloidin
  Phalloidin, is one of the main toxins of Amanita phalloides. 
It induces hepatotoxicity in rats at an intravenous dose of 
50 毺g/100 g b.w. Phalloidin also induces a cytolytic lesion. 
Phalloidin causes severe liver damage characterized by 
marked cholestasis, which is due in part to irreversible 
polymerization of actin filaments. Liver uptake of this toxin 
through the transporter OATP1B1 is inhibited by the bile 
acid derivative BALU-1, which does not inhibit the sodium-
dependent bile acid transporter NTCP[28]. 
6.14. Tamoxifen
Tamoxifen citrate (TAM) is a non-steroidal antiestrogen drug 
used in treatment and prevention of hormone dependent 
breast cancer. In high dose, it is a known liver carcinogen 
in rats, due to oxygen radical overproduction and lipid per 
oxidation via formation of lipid peroxy radicals. An ip dose of 
45 mg/kg/d of tamoxifen citrate in 0.1 mL dimethylsulfoxide 
and normal saline for 6 d induce hepatotoxicity in rats[30].
6.15. Tert-Butyl hydroperoxide (t-BHP)
  Hepatotoxicity and oxidative stress is induced in male rats 
at various times (0-24 h) after t-BHP (0, 0.2, 0.5, 1 or 3 mmol/
kg, ip) treatment. Serum hepatotoxicity parameters have been 
reported to increase from 2 h following 1 mmol/kg t-BHP 
and maximum values at 8 h. The elevation of hepatotoxic 
parameters and plasma MDA has been observed from 0.5 
to 1 mmol/kg t-BHP, respectively, in a dose-dependent 
manner. Being a short chain analog of lipid peroxide, t-BHP 
is metabolized into free radical intermediates by cytochrome 
P450 in hepatocytes, which initiate lipid peroxidation, 
glutathione depletion and cell damage[30]. 
6.16. Thioacetamide induced
  Thioacetamide interferes with the movement of RNA from 
the nucleus to cytoplasm which may cause membrane 
injury. A metabolite of thioacetamide (perhaps s-oxide) 
is responsible for hepatic injury. Thioacetamide reduce 
the number of viable hepatocytes as well as rate of oxygen 
consumption. It also decreases the volume of bile and its 
content i.e. bile salts, cholic acid and deoxycholic acid. I.P. 
dose of thioacetamide: 200 mg/kg, thrice weekly for 8 weeks 
induces hepatotoxicity[31].
7. Conclusion
  Drug discovery and development consists of a series of 
processes starting with the demonstration of pharmacological 
effects in experimental cell and animal models and 
ending with drug safety and efficacy studies in patients. A 
main limitation is often the unacceptable level of toxicity 
with the liver as the primary target organ. The study of 
hepatoprotective agents has thus become an important 
field of research. This article explains various types of 
hepatotoxins which are employed in the study the the 
antihepatotoxic or hepatoprotective agents.
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